Burden of Lymphoma in China, 1990-2019: an Analysis of the Global Burden of Diseases, Injuries, and Risk Factors Study 2019

Overview

Journal Aging (Albany NY)

Specialty Geriatrics

Date 2022 Apr 10

PMID 35398840

Authors

Weiping Liu

Jiangmei Liu

Yuqin Song

Xiaopei Wang

Lan Mi

Cai Cai

Donglu Zhao

Lijun Wang

Jun Ma

Jun Zhu

Affiliations

Soon will be listed here.

Abstract

Background: China is facing an aggravating disease burden of lymphoma. However, accurate information about lymphoma burden at the national and provincial levels is limited.

Results: The estimated number of disability-adjusted life years were 86,171.85 for Hodgkin lymphoma and 1,306,247.77 for non-Hodgkin lymphoma with the age-standardized rates of 4.95 and 71.00, respectively, per 100,000 population. There were estimated 9,468 new cases and 2,709 Hodgkin lymphoma-related deaths, and 91,954 new cases and 44,310 non-Hodgkin lymphoma-related deaths. Older individuals had a higher lymphoma burden. The age-standardized disability-adjusted life year rate in men was approximately two-folds higher than that in women. Moreover, disparities in lymphoma burden were observed across the provinces. Between 1990 and 2019, the disability-adjusted life year number decreased by 57.8% for Hodgkin lymphoma, and increased by 100.9% for non-Hodgkin lymphoma.

Conclusion: Burden of lymphoma showed heterogeneous change patterns varied according to sex, age, and provinces, with a steady decrease in Hodgkin lymphoma and a significant increase in non-Hodgkin lymphoma during the past three decades.

Methods: Following the analytical strategy used in the Global Burden of Diseases, Injuries, and Risk Factors Study 2019, age-, sex-, and province-specific incidence, mortality, and prevalence of Hodgkin lymphoma and non-Hodgkin lymphoma were analyzed. Lymphoma burden was assessed by incidence, mortality, prevalence, and disability-adjusted life year.

Citing Articles

Improving access to chimeric antigen receptor T-cells for refractory or relapsing diffuse large B cell lymphoma therapy in Asia.

Tan Y, Yoon D, Davies A, Buske C, Boo Y, Somasundaram N Discov Oncol. 2025; 16(1):181.

PMID: 39951161 PMC: 11828776. DOI: 10.1007/s12672-025-01860-5.

Loncastuximab tesirine in Chinese patients with relapsed or refractory diffuse large B-cell lymphoma: a multicenter, open-label, single-arm, phase II trial.

Lin N, Sun X, Zhou H, Zou L, Zhou K, Liu L Haematologica. 2024; 110(3):683-692.

PMID: 39234866 PMC: 11873689. DOI: 10.3324/haematol.2024.284973.

Contemporaneous symptom networks analysis in lymphoma patients during chemotherapy: protocol for a single-centre prospective cross-sectional study.

Chen X, Liu L, Li W, Lei L, Li W, Wu L BMJ Open. 2024; 14(8):e082822.

PMID: 39179280 PMC: 11344526. DOI: 10.1136/bmjopen-2023-082822.

Efficacy and Mechanism of Core Traditional Chinese Medicines for Treating Malignant Lymphoma based on Efficacy Studies: A Study Supported by Network Pharmacology and Molecular Docking.

Jin J, Ren S, Han B, Zhang W, Xu H, Yang J Curr Pharm Des. 2024; 30(33):2652-2666.

PMID: 39082169 DOI: 10.2174/0113816128308565240710114350.

The trend of lymphoma incidence in China from 2005 to 2017 and lymphoma incidence trend prediction from 2018 to 2035: a log-linear regression and Bayesian age-period-cohort analysis.

Lin K, Shao J, Cao Y, Lu L, Lei P, Chen X Front Oncol. 2024; 14:1297405.

PMID: 38868533 PMC: 11167089. DOI: 10.3389/fonc.2024.1297405.

References

. Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020; 396(10258):1250-1284. PMC: 7562819. DOI: 10.1016/S0140-6736(20)30750-9. View

Chen W, Zheng R, Zhang S, Zeng H, Zuo T, Xia C . Cancer incidence and mortality in China in 2013: an analysis based on urbanization level. Chin J Cancer Res. 2017; 29(1):1-10. PMC: 5348470. DOI: 10.21147/j.issn.1000-9604.2017.01.01. View

Chen W, Xia C, Zheng R, Zhou M, Lin C, Zeng H . Disparities by province, age, and sex in site-specific cancer burden attributable to 23 potentially modifiable risk factors in China: a comparative risk assessment. Lancet Glob Health. 2019; 7(2):e257-e269. DOI: 10.1016/S2214-109X(18)30488-1. View

. Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950-2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019. Lancet. 2020; 396(10258):1160-1203. PMC: 7566045. DOI: 10.1016/S0140-6736(20)30977-6. View

Liu W, Liu J, Song Y, Zeng X, Wang X, Mi L . Burden of lymphoma in China, 2006-2016: an analysis of the Global Burden of Disease Study 2016. J Hematol Oncol. 2019; 12(1):115. PMC: 6862726. DOI: 10.1186/s13045-019-0785-7. View

Liu W, Ji X, Song Y, Wang X, Zheng W, Lin N . Improving survival of 3760 patients with lymphoma: Experience of an academic center over two decades. Cancer Med. 2020; 9(11):3765-3774. PMC: 7286476. DOI: 10.1002/cam4.3037. View

Zeng H, Chen W, Zheng R, Zhang S, Ji J, Zou X . Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries. Lancet Glob Health. 2018; 6(5):e555-e567. DOI: 10.1016/S2214-109X(18)30127-X. View

Kocarnik J, Compton K, Dean F, Fu W, Gaw B, Harvey J . Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019: A Systematic Analysis for the Global Burden of Disease Study 2019. JAMA Oncol. 2021; 8(3):420-444. PMC: 8719276. DOI: 10.1001/jamaoncol.2021.6987. View

Liu W, Liu J, Song Y, Wang X, Zhou M, Wang L . Mortality of lymphoma and myeloma in China, 2004-2017: an observational study. J Hematol Oncol. 2019; 12(1):22. PMC: 6399942. DOI: 10.1186/s13045-019-0706-9. View

10.

Yu H . Universal health insurance coverage for 1.3 billion people: What accounts for China's success?. Health Policy. 2015; 119(9):1145-52. PMC: 7114832. DOI: 10.1016/j.healthpol.2015.07.008. View

11.

Liu W, Zhu J . Comments on (). Chin J Cancer Res. 2019; 31(5):738-739. PMC: 6856702. DOI: 10.21147/j.issn.1000-9604.2019.05.02. View

12.

Guo Q, Luo K, Hu R . The Spatial Correlations of Health Resource Agglomeration Capacities and Their Influencing Factors: Evidence from China. Int J Environ Res Public Health. 2020; 17(22). PMC: 7700579. DOI: 10.3390/ijerph17228705. View

13.

Goldstein J, Nastoupil L, Han X, Jemal A, Ward E, Flowers C . Disparities in survival by insurance status in follicular lymphoma. Blood. 2018; 132(11):1159-1166. PMC: 6137560. DOI: 10.1182/blood-2018-03-839035. View

14.

Chen M, Zhou G, Si L . Ten years of progress towards universal health coverage: has China achieved equitable healthcare financing?. BMJ Glob Health. 2020; 5(11). PMC: 7677383. DOI: 10.1136/bmjgh-2020-003570. View

15.

Darba J, Marsa A . Burden of Hodgkin and non-Hodgkin lymphoma in Spain over a 10-year period: productivity losses due to premature mortality. Expert Rev Pharmacoecon Outcomes Res. 2020; 21(1):87-92. DOI: 10.1080/14737167.2020.1769478. View

16.

. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020; 396(10258):1223-1249. PMC: 7566194. DOI: 10.1016/S0140-6736(20)30752-2. View

17.

Zhou L, Deng Y, Li N, Zheng Y, Tian T, Zhai Z . Global, regional, and national burden of Hodgkin lymphoma from 1990 to 2017: estimates from the 2017 Global Burden of Disease study. J Hematol Oncol. 2019; 12(1):107. PMC: 6805485. DOI: 10.1186/s13045-019-0799-1. View

18.

Palmarsdottir R, Ovlisen A, Severinsen M, Glimelius I, Smedby K, El-Galaly T . Socioeconomic impact of Hodgkin lymphoma in adult patients: a systematic literature review. Leuk Lymphoma. 2019; 60(13):3116-3131. DOI: 10.1080/10428194.2019.1613538. View

19.

Yuan Y, Yang L, Sun T, Li H, Zhu J, Song Y . [Analysis of lymphoma incidence in Beijing, 1998-2010]. Zhonghua Yu Fang Yi Xue Za Zhi. 2014; 48(8):669-73. View

20.

Yip W, Fu H, Chen A, Zhai T, Jian W, Xu R . 10 years of health-care reform in China: progress and gaps in Universal Health Coverage. Lancet. 2019; 394(10204):1192-1204. DOI: 10.1016/S0140-6736(19)32136-1. View